These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 8137284)
1. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction. Modjtahedi H; Eccles S; Box G; Styles J; Dean C Br J Cancer; 1993 Feb; 67(2):254-61. PubMed ID: 7679281 [TBL] [Abstract][Full Text] [Related]
3. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor. Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Masui H; Moroyama T; Mendelsohn J Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Hoffmann T; Hafner D; Ballo H; Haas I; Bier H Anticancer Res; 1997; 17(6D):4419-25. PubMed ID: 9494544 [TBL] [Abstract][Full Text] [Related]
7. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Fan Z; Masui H; Altas I; Mendelsohn J Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927 [TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Fan Z; Baselga J; Masui H; Mendelsohn J Cancer Res; 1993 Oct; 53(19):4637-42. PubMed ID: 8402640 [TBL] [Abstract][Full Text] [Related]
9. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134 [TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674 [TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Mendelsohn J J Natl Cancer Inst Monogr; 1992; (13):125-31. PubMed ID: 1389685 [TBL] [Abstract][Full Text] [Related]
14. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents. Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544 [TBL] [Abstract][Full Text] [Related]
15. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944 [TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559 [TBL] [Abstract][Full Text] [Related]
17. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346 [TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to the EGF receptor act as betacellulin antagonists. Modjtahedi H; Dean C Biochem Biophys Res Commun; 1996 Apr; 221(3):625-30. PubMed ID: 8630011 [TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Rubin Grandis J; Chakraborty A; Melhem MF; Zeng Q; Tweardy DJ Oncogene; 1997 Jul; 15(4):409-16. PubMed ID: 9242377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]